Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 10 Disease specific utility values used in PRIMEtime CE

From: PRIMEtime CE: a multistate life table model for estimating the cost-effectiveness of interventions affecting diet and physical activity

PRIMEtime CE disease outcome PRIMEtime CE ICD-10 codes Equivalent ICD-9 codes Available utility decrement from Sullivan et al. [80]a Utility value used in PRIMEtime CE (SE)
Ischaemic heart disease I20-I25 410–414 410: −0.063
411: −0.087
412: −0.037
413: −0.085
414: −0.063
Incident case: −0.071 (0.024)
Prevalent: −0.070 (0.015)
Stroke I60-I69 430–438 433: −0.035
435: − 0.033
436: − 0.117
437: − 0.031
438: − 0.073
Incident: − 0.094 (0.019)
Prevalent: − 0.046 (0.031)
Type two diabetes E11, E14 250.×0 250: − 0.071 − 0.071 (0.005)
Breast cancer C50 174, 175 174: − 0.019 − 0.019 (0.014)
Colon cancer C18-C20 153, 154.0, 154.1 153: − 0.067 − 0.067 (0.017)
Lung cancer C34 162.2–162.9 162: − 0.119 −0.119 (0.043)
Stomach cancer C16 151 151: −0.071 −0.071 (0.105)
Liver cancer C22 155 155: −0.093 −0.093 (0.044)
Kidney cancer C64 189.0 189: −0.048 −0.048 (0.041)
Pancreatic cancer C25 157 195: −0.086 −0.086 (0.027)
Liver disease K70, K74 571.0–571.3, 571.5, 571.6, 571.9 571: −0.083 −0.083 (0.031)
  1. areported utility decrement controlled for age, comorbidity, gender, race, ethnicity, income, and education; SE standard error